Azenta Life Sciences

Azenta Life Sciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

Azenta Life Sciences is a strategic enabler in the life sciences value chain, offering a comprehensive portfolio that spans automated sample storage systems, consumables, cloud-based informatics (LIMS), and GENEWIZ multiomics services. Its strategy focuses on integrating hardware, software, and services to solve critical bottlenecks in biobanking, clinical trials, and cell & gene therapy. As a publicly traded company with a ~$1B valuation, Azenta has evolved through strategic acquisitions and organic growth to become a dedicated partner for pharmaceutical, biotech, and academic research organizations worldwide.

DiagnosticsGenetics & Genomics

Technology Platform

An integrated ecosystem of automated sample storage hardware, tracking consumables, cloud-based informatics software (LIMS), and multiomics services, designed to manage the entire biological sample lifecycle.

Funding History

1
Total raised:$50M
Series A$50M

Opportunities

Major growth drivers include the expansion of biobanking, the complexity of cell & gene therapy logistics, and the outsourcing of sample management by pharmaceutical companies.
Azenta's integrated platform is uniquely positioned to capture value across these trends by offering efficiency, compliance, and data integrity.

Risk Factors

Key risks include sensitivity to biopharma R&D spending cycles, intense competition across all business segments, and execution risks associated with integrating its broad portfolio of hardware, software, and services into a seamless customer experience.

Competitive Landscape

Azenta competes with focused players in automated storage (Hamilton, Tecan), consumables (Thermo Fisher), LIMS (LabVantage), and multiomics services (Eurofins, Twist). Its primary advantage is its integrated, full-stack ecosystem, which creates switching costs and a 'one-stop-shop' value proposition.